Reports of an impressive effectiveness and safety of an experimental drug against a common type of breast cancer, in is mid-stage trial has notched up the shares of Pfizer Inc by almost two percent.
Post these trials, Pfizer have planned late-stage trials on a large scale during next year. If the drug is approved, it could fetch the drug-maker increased sales amounting to multi-billion dollars according to analysts.
The drug under trail was, ‘PD-0332991’. It successfully delayed worsening of symptoms associated with a common form of breast cancerin post-menstrual women. The new drug which blocks enzymes known as CDK4 and 6 Kinases was taken alongside another standard drug called ‘letrozole’ in women who were positive to estrogen receptors.
This proved that tumors grew in response to estrogen while HER2 protein is not responsible for causing the cancer. In all, these women constitute 60 percent of all breast cancer patients. In case of patients who were administered both the drugs, it took an average of 26.1 months before the condition of the tumor worsened. This compared with 7.5 months for the tumor to worsen in patients taking letrozole and not PD-0332291. This difference of 18.6 months for the condition of the tumor to worsen is regarded as being significant statistically.
The side effects of taking this drug combination included fatigue, anemia and neutropenia. Neutopenia is a condition in which the white blood cells called neutrophils decline putting the patient at a high risk for getting infections. Mark Schoenebaum, an analyst with the ISI group of PD-0332991 said that if the new drug is approved in a front-line breast cancer setting, it has the potential to generate approximately two to six billion dollars in revenue in worldwide sales by treating these types of breast cancer patients.
He said that the medicine could generate significant increase in the revenue of Pfizer if it gets necessary clearance from the regulators.
Get our Tips and Tricks to your Inbox